AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
carbamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 4264 | 57-13-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AURKB,AURKC,AXL,BMX,BRAF,CAMK2B,CAMK2D,CDK1,CDK2,CDK3,CDK5,CDK9,CHEK1,CLK4,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,GRK2,GSK3B,IKBKB,IRAK1,IRAK3,ITK,JAK1,JAK2,KDR,KIT,LYN,MAP2K6,MAP3K1,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAP4K5,MAPK7,MAPK9,MARK4,MET,MTOR,NTRK1,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2 | 79 | |||
| kinase-selectivity-class | AAK1,ACVR2A,ACVR2B,ALK,AURKA,AXL,BMX,BRAF,CAMK2B,CAMK2D,CDK1,CDK9,CSF1R,DDR1,DYRK1B,EGFR,EIF2AK3,FGFR1,FLT3,GRK2,IKBKB,IRAK1,JAK1,JAK2,LRRK2,MAP2K3,MAP2K6,MAP3K10,MAP3K11,MAP3K14,MAP3K21,MAP4K1,MAP4K3,MAPK7,MARK4,NTRK1,NUAK1,PRKCD,SIK2,SIK3,STK33,STK4,TEK,TNK1,TTK,ULK1,ULK2 | 47 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Oct. 5, 1966 | FDA | HOSPIRA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndrome | 105.04 | 16.29 | 41 | 3854 | 27982 | 90596570 |
| Decreased appetite | 27.44 | 16.29 | 54 | 3841 | 376486 | 90248066 |
| Anastomotic leak | 26.28 | 16.29 | 6 | 3889 | 641 | 90623911 |
| Hypertension | 24.59 | 16.29 | 58 | 3837 | 457474 | 90167078 |
| Platelet count decreased | 23.20 | 16.29 | 29 | 3866 | 136940 | 90487612 |
| Pseudomembranous colitis | 23.16 | 16.29 | 8 | 3887 | 3860 | 90620692 |
| Hepatic function abnormal | 21.49 | 16.29 | 17 | 3878 | 46271 | 90578281 |
| Enterocolitis | 21.46 | 16.29 | 10 | 3885 | 10480 | 90614072 |
| Neoplasm skin | 20.78 | 16.29 | 7 | 3888 | 3135 | 90621417 |
| Dermatitis exfoliative | 20.37 | 16.29 | 8 | 3887 | 5528 | 90619024 |
| Dermatitis exfoliative generalised | 20.29 | 16.29 | 8 | 3887 | 5585 | 90618967 |
| Change of bowel habit | 18.78 | 16.29 | 6 | 3889 | 2277 | 90622275 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndrome | 130.59 | 19.71 | 49 | 2642 | 20533 | 42598111 |
| Decreased appetite | 40.39 | 19.71 | 55 | 2636 | 193082 | 42425562 |
| Hepatic function abnormal | 29.31 | 19.71 | 25 | 2666 | 51542 | 42567102 |
| Hepatic encephalopathy | 28.84 | 19.71 | 16 | 2675 | 16426 | 42602218 |
| Hepatocellular carcinoma | 26.27 | 19.71 | 12 | 2679 | 8182 | 42610462 |
| Blood bilirubin increased | 25.06 | 19.71 | 21 | 2670 | 42231 | 42576413 |
| Platelet count decreased | 21.02 | 19.71 | 34 | 2657 | 138547 | 42480097 |
| Diarrhoea | 20.86 | 19.71 | 70 | 2621 | 460779 | 42157865 |
| Hypocalcaemia | 19.99 | 19.71 | 16 | 2675 | 30157 | 42588487 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Palmar-plantar erythrodysaesthesia syndrome | 229.80 | 16.52 | 85 | 5746 | 40940 | 110542528 |
| Hepatic function abnormal | 52.56 | 16.52 | 41 | 5790 | 89254 | 110494214 |
| Platelet count decreased | 48.17 | 16.52 | 60 | 5771 | 230383 | 110353085 |
| Decreased appetite | 47.86 | 16.52 | 88 | 5743 | 475758 | 110107710 |
| Hepatic encephalopathy | 30.89 | 16.52 | 19 | 5812 | 28237 | 110555231 |
| Blood bilirubin increased | 28.57 | 16.52 | 27 | 5804 | 75945 | 110507523 |
| Diarrhoea | 27.02 | 16.52 | 125 | 5706 | 1139380 | 109444088 |
| Hepatocellular carcinoma | 26.18 | 16.52 | 12 | 5819 | 9868 | 110573600 |
| Dermatitis exfoliative | 24.59 | 16.52 | 12 | 5819 | 11335 | 110572133 |
| Hypertension | 24.01 | 16.52 | 70 | 5761 | 510014 | 110073454 |
| Enterocolitis | 23.97 | 16.52 | 14 | 5817 | 18935 | 110564533 |
| Colon cancer | 23.08 | 16.52 | 13 | 5818 | 16430 | 110567038 |
| Malignant neoplasm progression | 22.37 | 16.52 | 36 | 5795 | 174531 | 110408937 |
| Aspartate aminotransferase increased | 21.89 | 16.52 | 34 | 5797 | 159902 | 110423566 |
| Skin exfoliation | 21.86 | 16.52 | 25 | 5806 | 87626 | 110495842 |
| Anastomotic leak | 20.67 | 16.52 | 6 | 5825 | 1346 | 110582122 |
| Bladder transitional cell carcinoma recurrent | 19.79 | 16.52 | 4 | 5827 | 195 | 110583273 |
| Neoplasm skin | 19.24 | 16.52 | 7 | 5824 | 3197 | 110580271 |
| Alanine aminotransferase increased | 18.42 | 16.52 | 34 | 5797 | 183739 | 110399729 |
| Anti-erythropoietin antibody negative | 17.88 | 16.52 | 4 | 5827 | 317 | 110583151 |
| Pseudomembranous colitis | 17.68 | 16.52 | 8 | 5823 | 6383 | 110577085 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | B05BC02 | BLOOD AND BLOOD FORMING ORGANS BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS I.V. SOLUTIONS Solutions producing osmotic diuresis |
| ATC | D02AE01 | DERMATOLOGICALS EMOLLIENTS AND PROTECTIVES EMOLLIENTS AND PROTECTIVES Carbamide products |
| ATC | D02AE51 | DERMATOLOGICALS EMOLLIENTS AND PROTECTIVES EMOLLIENTS AND PROTECTIVES Carbamide products |
| CHEBI has role | CHEBI:33287 | fertilizer |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:35526 | hypoglycemic agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50177 | dermatologic drug |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:64577 | flour treatment agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:75772 | <em>Saccharomyces cerevisiae </em> metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:77746 | human metabolite |
| CHEBI has role | CHEBI:83056 | <em>Daphnia magna</em> metabolite |
Related Drugs by ATC class:
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Impacted cerumen | indication | 18070006 | |
| Atopic dermatitis | indication | 24079001 | DOID:3310 |
| Contact dermatitis | indication | 40275004 | DOID:2773 |
| Seborrheic dermatitis | indication | 50563003 | DOID:8741 |
| Pityriasis versicolor | indication | 56454009 | DOID:9060 |
| Pityriasis simplex | indication | 200767005 | |
| Eruption of skin | indication | 271807003 | DOID:0050486 |
| Acne vulgaris | off-label use | 88616000 | |
| Hyperkeratosis | off-label use | 396228006 | |
| Rosacea | off-label use | 398909004 | DOID:8881 |
| Injury of ear | contraindication | 2999009 | |
| Otalgia | contraindication | 16001004 | |
| Chronic purulent otitis media | contraindication | 38394007 | DOID:14247 |
| Perforation of tympanic membrane | contraindication | 60442001 | |
| Procedure on ear | contraindication | 118891001 | |
| Infection of ear | contraindication | 129127001 | |
| Irritation of ear | contraindication | 162360008 | |
| Itching of ear | contraindication | 699392007 | |
| Ear Redness | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 11.96 | acidic |
| pKa2 | 13.39 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Olfactory receptor 51E2 | GPCR | EC50 | 7.64 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018430 | VUID |
| N0000146756 | NUI |
| D00023 | KEGG_DRUG |
| 4018430 | VANDF |
| C0041942 | UMLSCUI |
| CHEBI:16199 | CHEBI |
| URE | PDB_CHEM_ID |
| CHEMBL985 | ChEMBL_ID |
| DB03904 | DRUGBANK_ID |
| 1176 | PUBCHEM_CID |
| 11002 | RXNORM |
| 5656 | MMSL |
| 9476 | MMSL |
| d04207 | MMSL |
| 002015 | NDDF |
| 002273 | NDDF |
| 16858004 | SNOMEDCT_US |
| 387092000 | SNOMEDCT_US |
| D014508 | MESH_DESCRIPTOR_UI |
| 4539 | IUPHAR_LIGAND_ID |
| 8W8T17847W | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Urea Cream 40% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16477-340 | CREAM | 400 mg | TOPICAL | unapproved drug other | 16 sections |
| Urea Cream 40% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16477-340 | CREAM | 400 mg | TOPICAL | unapproved drug other | 16 sections |
| Urea Cream 41% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16477-341 | CREAM | 410 mg | TOPICAL | unapproved drug other | 16 sections |
| Urea Cream 41% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16477-341 | CREAM | 410 mg | TOPICAL | unapproved drug other | 16 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24470-939 | CREAM | 400 mg | TOPICAL | unapproved drug other | 10 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24470-962 | LOTION | 400 mg | TOPICAL | unapproved drug other | 9 sections |
| Urea 40% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 39328-019 | CREAM | 400 mg | TOPICAL | Unapproved drug other | 18 sections |
| CEM-Urea | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42546-100 | SOLUTION | 0.45 mL | TOPICAL | unapproved drug other | 13 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44523-617 | CREAM | 400 mg | TOPICAL | unapproved drug other | 12 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44523-618 | CREAM | 200 mg | TOPICAL | unapproved drug other | 11 sections |
| Urea 39% Cream | HUMAN PRESCRIPTION DRUG LABEL | 1 | 44523-801 | CREAM | 390 mg | TOPICAL | unapproved drug other | 16 sections |
| Urea 20 | HUMAN OTC DRUG LABEL | 1 | 50268-820 | GEL | 200 mg | TOPICAL | unapproved drug other | 12 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-872 | CREAM | 40 g | TOPICAL | unapproved drug other | 13 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54295-308 | CREAM | 40 g | TOPICAL | unapproved drug other | 12 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54295-311 | CREAM | 39 g | TOPICAL | unapproved drug other | 12 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54295-312 | LOTION | 40 g | TOPICAL | unapproved drug other | 12 sections |
| Urea 40 Percent | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58657-487 | CREAM | 400 mg | TOPICAL | unapproved drug other | 16 sections |
| Urea 40 Percent | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58657-487 | CREAM | 400 mg | TOPICAL | unapproved drug other | 16 sections |
| Urea Cream 40 Percent | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58657-489 | CREAM | 400 mg | TOPICAL | unapproved drug other | 12 sections |
| Urea Cream 40 Percent | HUMAN PRESCRIPTION DRUG LABEL | 1 | 58657-489 | CREAM | 400 mg | TOPICAL | unapproved drug other | 12 sections |
| Urea 39.5% with 2% Salicylic Acid | HUMAN PRESCRIPTION DRUG LABEL | 2 | 59088-210 | CREAM | 39.50 g | TOPICAL | unapproved drug other | 16 sections |
| Uracin 20% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59088-257 | CREAM | 0.20 g | TOPICAL | unapproved drug other | 17 sections |
| Urea 41% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59088-489 | CREAM | 410 mg | TOPICAL | unapproved drug other | 16 sections |
| Urea 39.5% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59088-698 | CREAM | 395 mg | TOPICAL | unapproved drug other | 16 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2036 | CREAM | 39 g | TOPICAL | unapproved drug other | 13 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-2040 | LOTION | 40 g | TOPICAL | unapproved drug other | 13 sections |
| Urea 40 Percent | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-9267 | CREAM | 400 mg | TOPICAL | unapproved drug other | 16 sections |
| UREA | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68134-801 | CREAM | 400 mg | TOPICAL | unapproved drug other | 12 sections |
| Umecta MousseUrea | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68712-020 | AEROSOL, FOAM | 400 mg | TOPICAL | unapproved drug other | 12 sections |
| Not Applicable | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69336-810 | CREAM | 42 mg | TOPICAL | unapproved drug other | 12 sections |